全球過敏疫苗市場－按過敏類型、疫苗類型、應用、最終用戶、地區和競爭格局分類的行業規模、佔有率、趨勢、機會和預測（2021-2031年）

全球過敏疫苗市場預計將從 2025 年的 14.2 億美元成長到 2031 年的 22.9 億美元，複合年成長率為 8.29%。

這些疫苗，技術上稱為過敏原免疫療法，其作用機制是透過向患者注射遞增劑量的特定過敏原，以促進長期免疫耐受性。推動這一市場發展的關鍵因素包括全球慢性過敏性呼吸系統疾病的盛行率上升，以及氣候變遷等環境變遷導致花粉季延長、過敏原暴露增加。根據美國氣喘和過敏基金會2024年的數據，美國有超過1億人患有過敏性疾病，這表明迫切需要針對這些疾病根本原因而非僅緩解症狀的緩解疾病療法。

儘管市場需求強勁，但患者依從性和有效治療所需的長期療程在市場中面臨嚴峻挑戰。需要多年治療，且經常涉及頻繁的皮下注射或每日舌下給藥，這通常會導致較高的停藥率。這種長期依從性難題阻礙了免疫療法的廣泛應用，並限制了其潛在的產生收入。

市場促進因素

全球慢性過敏性呼吸道疾病和食物相關疾病發生率的不斷上升是推動全球過敏疫苗市場發展的主要因素。快速的都市化和日益嚴重的環境污染導致過敏率不斷攀升，迫切需要超越單純症狀管理的長期免疫療法干預措施。這種成長趨勢在成年人中尤其顯著，使他們成為新型脫敏策略的重要目標人口。例如，根據英國食品標準局2024年5月發布的《成人食物過敏盛行率報告》，約6%的英國成年人患有臨床確診的食物過敏，為新興候選疫苗提供了龐大的潛在市場。

同時，便利的舌下免疫療法（SLIT）製劑獲得越來越多的監管核准，正在改變治療格局，有效解決了傳統皮下注射通用的依從性問題。這些非侵入性、居家服用的藥片正日益受到患者和醫療服務提供者的青睞，減輕了患者頻繁就診的負擔，並提高了治療完成率。這種給藥方式的轉變正在推動實際的商業性成功。 ALK-Abello公司報告稱，其過敏免疫療法片劑在2024年2月的該地貨幣銷售額成長了11%，這證實了患者對便利治療方案的接受度正在加速提高。兒童需求進一步推動了這一趨勢。倫敦帝國學院指出，2024年學齡前兒童食物過敏的盛行率將達到4%，這表明所有年齡層對有效治療方法的需求仍然存在。

市場挑戰

全球過敏疫苗市場成長的主要障礙在於難以確保患者持續堅持嚴格的長期治療方案，而這對於確保療效至關重要。過敏原免疫療法通常需要3-5年的長期治療，包括頻繁的皮下注射或每日舌下含服。這種長期治療對患者來說負擔極重，會導致“治療疲勞”，並常常導致患者在建立長期耐受性之前就停止治療。因此，高治療中斷率直接減少了生產商的持續收入，並限制了市場的整體擴張，因為治療的全部價值和經濟回報只有在完成整個療程後才能實現。

近期臨床數據凸顯了病患流失的嚴重性。 2024年，美國過敏、氣喘和免疫學會（ACAAI）在其年度科學會議上發表了一項縱向研究，結果顯示，五年內有42.8%的患者停止了免疫療法。此類統計數據凸顯了患者治療體系的脆弱性。當近一半的患者無法完成整個療程時，潛在的患者群體實際上就減少了。這種低依從性不僅直接導致收入下降，也使得醫療服務提供者不願開立此類治療方法，他們擔心長期投入的時間和資源無法帶來預期的臨床療效。

市場趨勢

類病毒顆粒（VLP）疫苗平台的進步正在重新定義過敏治療，其提供的短期免疫調節療法克服了傳統萃取物療法在安全性和療程方面的限制。透過利用重組技術增強免疫識別，這些候選疫苗有望顯著縮短長達數年的治療通訊協定。近期臨床結果也支持了這項進展。 2024年12月，Allergy Therapeutics公司公佈了PROTECT試驗的中期數據，結果顯示，接受該公司VLP花生候選疫苗治療的患者在皮膚點刺試驗後，風團面積縮小了48%，而安慰劑組僅縮小了8%。這凸顯了該平台在快速脫敏和提高治療維持率方面的潛力。

同時，經皮免疫療法貼片的研發正在改變整個產業，尤其是在需要非侵入性治療的兒童食物過敏領域。這些貼片利用皮膚自身的免疫系統誘導耐受，最大限度地降低了口服和注射給藥途徑相關的過敏反應風險。商業化進程正在加速，DBV Technologies公司於2024年10月宣布，其關鍵性VITESSE III期臨床試驗已招募了654名受試者。這項進展凸顯了產業向基於皮膚的給藥系統策略轉型，以滿足食物過敏領域巨大的市場需求。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球過敏疫苗市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依過敏類型（過敏性氣喘、貓毛過敏、草花粉過敏、花生過敏、季節性過敏性鼻炎、樹木花粉過敏）
  • 依疫苗類型分類（貓過敏疫苗、家塵蟎過敏疫苗、注射型MPL過敏疫苗、花生過敏疫苗、豚草過敏免疫療法疫苗）
  • 依應用領域（愛滋病、腫瘤、呼吸系統）
  • 按最終使用者（居家醫療、醫院、專科診所等）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美過敏疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲過敏疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區過敏疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲過敏疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美洲過敏疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球過敏疫苗市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Stallergenes Greer PLC
• Allergy Therapeutics PLC
• HAL Allergy BV
• Jubilant HollisterStier Allergy
• Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
• Dermapharm AG
• Merck KGaA
• Aimmune Therapeutics Inc.
• Biomay AG

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Allergy Vaccine Market is projected to expand from USD 1.42 Billion in 2025 to USD 2.29 Billion by 2031, reflecting a CAGR of 8.29%. These vaccines, technically known as allergen immunotherapy, function by administering incrementally increasing doses of a specific allergen to the patient to foster long-term immune tolerance. The primary factors driving this market include the rising global prevalence of chronic allergic respiratory diseases and environmental changes, such as climate shifts that extend pollen seasons and heighten allergen exposure. Data from the Asthma and Allergy Foundation of America in 2024 indicates that allergic conditions affect over 100 million people in the United States, highlighting a critical need for disease-modifying treatments that target the root causes of these pathologies rather than simply providing temporary symptom relief.

Despite strong demand, the market faces significant hurdles regarding patient compliance and the extended duration required for effective treatment. The necessity for multi-year regimens, which involve either frequent subcutaneous injections or daily sublingual administration, often results in high discontinuation rates. This difficulty in maintaining long-term commitment hampers the broader adoption of these immunotherapeutic solutions and restricts their potential revenue generation.

Market Driver

The escalating global incidence of chronic allergic respiratory and food-related disorders serves as the primary force propelling the Global Allergy Vaccine Market. Rapid urbanization and rising environmental pollution are increasing sensitization rates, creating an urgent requirement for long-term immunotherapeutic interventions beyond mere symptom management. This surge is particularly noticeable among adults, establishing a significant demographic for novel desensitization strategies. For instance, the Food Standards Agency's May 2024 report on adult food allergy prevalence revealed that approximately 6% of the adult population in the United Kingdom now has a clinically confirmed food allergy, representing a vastly expanded addressable market for emerging vaccine candidates.

Simultaneously, the increasing regulatory approval of convenient Sublingual Immunotherapy (SLIT) formulations is transforming the treatment landscape by addressing the adherence challenges common with traditional subcutaneous injections. Both patients and healthcare providers are favoring these non-invasive, home-administered tablets, as they reduce the burden of frequent clinic visits and improve therapy completion rates. This shift in delivery preference is driving tangible commercial success; ALK-Abello reported in February 2024 that sales of its allergy immunotherapy tablets grew by 11% in local currencies, underscoring the accelerated adoption of these patient-friendly options. This demand is further reinforced by pediatric needs, with Imperial College London noting in 2024 that food allergy prevalence in preschool-aged children has reached 4%, signaling a sustained need for effective therapies across all age groups.

Market Challenge

A major obstacle hindering the growth of the Global Allergy Vaccine Market is the difficulty in ensuring patient adherence to the rigorous and lengthy treatment regimens necessary for efficacy. Allergen immunotherapy requires a multi-year commitment, typically lasting three to five years, involving either frequent subcutaneous injections or daily sublingual doses. This prolonged duration imposes a significant burden on patients, often leading to "treatment fatigue," where individuals abandon therapy before long-term tolerance is achieved. Consequently, high discontinuation rates directly reduce recurring revenue streams for manufacturers and limit overall market expansion, as the full therapeutic value and financial return are only realized upon course completion.

The severity of this attrition is highlighted by recent clinical data. In 2024, the American College of Allergy, Asthma & Immunology (ACAAI) presented a longitudinal study at their Annual Scientific Meeting revealing that 42.8% of patients discontinued immunotherapy over a five-year period. Such statistics emphasize the fragility of the patient pipeline; when nearly half of initiated patients fail to complete the full regimen, the market's potential addressable audience effectively shrinks. This pattern of non-compliance not only diminishes direct sales but also causes hesitation among healthcare providers to prescribe these therapies, fearing that the long-term investment of time and resources will not yield the desired clinical outcomes.

Market Trends

Advancements in Virus-Like Particle (VLP) Vaccine Platforms are redefining allergy treatment by providing short-course immunomodulation that addresses the safety and duration limitations of traditional extracts. These candidates utilize recombinant technology to improve immune recognition, potentially condensing multi-year protocols into much shorter regimens. This progress is supported by recent clinical results; in December 2024, Allergy Therapeutics reported positive interim data from the PROTECT Trial, showing that patients treated with their VLP Peanut candidate experienced a 48% reduction in wheal size after skin-prick testing, compared to an 8% reduction in the placebo group, underscoring the platform's potential for rapid desensitization and better adherence.

Concurrently, the development of Epicutaneous Immunotherapy Patches is reshaping the sector, particularly for pediatric food allergies requiring non-invasive solutions. By leveraging the skin's immune system to induce tolerance, these patches minimize the anaphylactic risks associated with oral or injectable routes. Commercialization efforts are intensifying; DBV Technologies announced in October 2024 that it had enrolled 654 subjects in its pivotal VITESSE Phase 3 trial. This development confirms the industry's strategic pivot toward skin-based delivery systems to capture the substantial demand within the food allergy segment.

Key Market Players

• Stallergenes Greer PLC
• Allergy Therapeutics PLC
• HAL Allergy BV
• Jubilant HollisterStier Allergy
• Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
• Dermapharm AG
• Merck KGaA
• Aimmune Therapeutics Inc.
• Biomay AG

Report Scope

In this report, the Global Allergy Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Allergy Vaccine Market, By Allergy Type

• Allergic Asthma
• Cat Dander Allergy
• Grass Pollen Hypersensitivity
• Peanut Hypersensitivity
• Seasonal Allergic Rhinitis
• Tree Pollen Hypersensitivity

Allergy Vaccine Market, By Vaccine Type

• Cat Allergy Vaccine
• House Dust Mite Allergy Vaccine
• Injectable MPL Allergy Vaccine
• Peanut Allergy Vaccine
• Ragweed Allergy Immunotherapy Vaccine

Allergy Vaccine Market, By Application

• HIV
• Oncology
• Respiratory

Allergy Vaccine Market, By End User

• Homecare
• Hospitals
• Specialty Clinics
• Others

Allergy Vaccine Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Allergy Vaccine Market.

Available Customizations:

Global Allergy Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Allergy Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Allergy Type (Allergic Asthma, Cat Dander Allergy, Grass Pollen Hypersensitivity, Peanut Hypersensitivity, Seasonal Allergic Rhinitis, Tree Pollen Hypersensitivity)
  • 5.2.2. By Vaccine Type (Cat Allergy Vaccine, House Dust Mite Allergy Vaccine, Injectable MPL Allergy Vaccine, Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine)
  • 5.2.3. By Application (HIV, Oncology, Respiratory)
  • 5.2.4. By End User (Homecare, Hospitals, Specialty Clinics, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Allergy Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Allergy Type
  • 6.2.2. By Vaccine Type
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Allergy Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Allergy Type
      • 6.3.1.2.2. By Vaccine Type
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Allergy Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Allergy Type
      • 6.3.2.2.2. By Vaccine Type
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Allergy Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Allergy Type
      • 6.3.3.2.2. By Vaccine Type
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Allergy Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Allergy Type
  • 7.2.2. By Vaccine Type
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Allergy Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Allergy Type
      • 7.3.1.2.2. By Vaccine Type
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. France Allergy Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Allergy Type
      • 7.3.2.2.2. By Vaccine Type
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Allergy Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Allergy Type
      • 7.3.3.2.2. By Vaccine Type
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Allergy Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Allergy Type
      • 7.3.4.2.2. By Vaccine Type
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Allergy Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Allergy Type
      • 7.3.5.2.2. By Vaccine Type
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia Pacific Allergy Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Allergy Type
  • 8.2.2. By Vaccine Type
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Allergy Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Allergy Type
      • 8.3.1.2.2. By Vaccine Type
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Allergy Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Allergy Type
      • 8.3.2.2.2. By Vaccine Type
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Allergy Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Allergy Type
      • 8.3.3.2.2. By Vaccine Type
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Allergy Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Allergy Type
      • 8.3.4.2.2. By Vaccine Type
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Allergy Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Allergy Type
      • 8.3.5.2.2. By Vaccine Type
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. Middle East & Africa Allergy Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Allergy Type
  • 9.2.2. By Vaccine Type
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Allergy Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Allergy Type
      • 9.3.1.2.2. By Vaccine Type
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Allergy Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Allergy Type
      • 9.3.2.2.2. By Vaccine Type
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Allergy Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Allergy Type
      • 9.3.3.2.2. By Vaccine Type
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. South America Allergy Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Allergy Type
  • 10.2.2. By Vaccine Type
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Allergy Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Allergy Type
      • 10.3.1.2.2. By Vaccine Type
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Allergy Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Allergy Type
      • 10.3.2.2.2. By Vaccine Type
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Allergy Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Allergy Type
      • 10.3.3.2.2. By Vaccine Type
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Allergy Vaccine Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Stallergenes Greer PLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Allergy Therapeutics PLC
• 15.3. HAL Allergy BV
• 15.4. Jubilant HollisterStier Allergy
• 15.5. Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
• 15.6. Dermapharm AG
• 15.7. Merck KGaA
• 15.8. Aimmune Therapeutics Inc.
• 15.9. Biomay AG

16. Strategic Recommendations

17. About Us & Disclaimer